Catalog No.: PC-21658Not For Human Use, Lab Use Only.
AM-9022 (AM9022) is a potent, selective and orally active mitotic kinesin KIF18A inhibitor with IC50 of 47 nM in kinesin-8 microtubule (MT)-ATPase motor assays.
AM-9022 (AM9022) is a potent, selective and orally active mitotic kinesin KIF18A inhibitor with IC50 of 47 nM in kinesin-8 microtubule (MT)-ATPase motor assays.
AM-9022 exhibits good specificity against a panel of diverse kinesin motor proteins, except for the KIF19A motor (IC50=926 nM).
AM-9022 shows cellular EC50 of 42 and 37 nM for cell line pH3+ and PCM foci in mitotic image assays respectively.
AM-9022 has similar inhibitory effects on the motor activity of human and mouse KIF18A.
AM-9022 (30 mg per kg, p.o.) increased pH3 mitotic marker levels in OVCAR-3 tumors by 3.4-fold in the OVCAR-3 HGSOC CDX tumor model, inhibited tumor growth with evidence of TR (95% TR) and no body weight loss.
AM-9022 administered at 30 and 100 mg per kg inhibited tumor growth with evidence of TR (16% and 94% TR, respectively) at well-tolerated doses in JIMT-1 breast cancer CDX tumor model.
